EKC, HIV Results and Broad-Spectrum Nanoviricides Capability Presented

NanoViricides, Inc., said that Anil R. Diwan, PhD, President of the Company, was a participant in a panel on global pharmaceutical strategies at the Fourth Annual Swedish-American Life Sciences Summit held August 20-22, 2008 in Stockholm, Sweden. Speaking in front of a large pharmaceutical and life sciences finance industry group, he enumerated the accomplishments of the Company. He also presented his thoughts on the Company’s global strategy for supplying nanoviricides treatments for serious viral diseases to both developed and developing countries.

Dr. Diwan was invited as a panel member on the panel discussion “Emerging Life Sciences in a Global Context- A New Necessity” held last Friday. After discussing the Company’s accomplishments, he spoke about the successes of the nanoviricides technology. In response to a question, he said that the Company has a strong focus on commercially important disease targets such as Influenza, Bird Flu, viral diseases of the eye, HIV, and Hepatitis C. He added that the Company has developed a unique broad-spectrum antiviral technology that can work well against a large number of different viruses. Using such agents, it will be possible to develop cost-effective treatment strategies against lethal diseases of the developing world such as Rabies, Dengue virus, and many others. Many of these diseases are now being seen more frequently in developed countries also.

The Fourth SALSS featured leaders of Life Sciences industry in both Sweden and the United States. This forum brought together key pharmaceutical executives, entrepreneurs, venture capitalists and financiers, and key scientists from both countries in an invitation-only open-discussion format. (http://www.marketwatch.com/news/story/swedish-american-life -science-summit-stockholm/story.aspx?guid=%7B0D2BC44F-BFBF-4F8A-ACA8 -55E5DCEAFC45%7D&dist=hppr).

Posted August 25th. 2008

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback